Orthofix Medical Inc. (OFIX)
Healthcare
- Fundamental
- 3
- Sentiment
- 2
- Technical
- 2
Do Nothing: qualitativeScore is 2 (below required floor of 3), and avgDollarVolume20 is $4.33M (below the $5M liquidity floor).
Company overview
Orthofix Medical Inc., headquartered in Lewisville, Texas, is a global medical technology company specializing in devices and biologics. It operates through two segments: Global Spine, which focuses on bone growth stimulators and spinal surgical products, and Global Orthopedics, which develops specialized orthopedic products for fracture repair and bone reconstruction. The company distributes its products through a comprehensive sales network to physicians, hospitals, and surgery centers.
Fundamental
fairOrthofix shows improving revenue and strong gross margins, but remains loss-making with execution risks.
Orthofix is showing gradual top-line improvement and strong gross margins, but it remains GAAP loss-making and recent interim cash flow was negative. Liquidity and covenant compliance look acceptable (cash about $104M and current ratio about 2.8 as of June 30, 2026) and management raised 2026 guidance, yet legal settlements and the need to translate gross profit into durable operating income are key uncertainties. Valuation is inexpensive on an EV/Sales basis (about 0.65× FY2025 sales), reflecting execution risk.
Sentiment
weakMedia and sell-side sentiment is cautious, with recent earnings not providing a clear catalyst.
Near-term narrative is dominated by Q2 results/guidance (announced) that were met with a beat-but-stock-drops framing and a sell-side price-target cut. Media sentiment cooled from mildly positive in the prior 30–90d (polarity_score ~+0.18) to neutral in the last ~14d (≈0.00), and a moderate red-flag cap is applied due to confirmed pending securities litigation (no regulator-confirmed investigation surfaced in the last 90d).
Technical
weakThe stock is stabilizing post-gap-down but remains below key moving averages, indicating a bearish trend.
The 8/5 earnings gap-down broke OFIX below its short-, intermediate-, and long-term trend stack, and the stock still has not reclaimed SMA20/50/200 or EMA9/21; oversold conditions are present, but MACD remains negative and ADX confirms the dominant downtrend.
You’re looking at 2026-08-15 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.